

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

NCT06457425

Status	RECRUITING
Phase	Phase 2
Sponsor	Chengdu Zenitar Biomedical Technology Co., Ltd
Enrollment	75 participants

Key Eligibility Criteria

Inclusion (26)

- Age e 18 years, no gender restrictions;
 - Diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) according to IWG-MRT criteria;
 - Evaluated as intermediate-2 or high-risk myelofibrosis according to the Dynamic International Prognostic Scoring System (DIPSS) risk classification;
 - Expected survival e 24 weeks;
 - ECOG score of 0-2;
- ... and 21 more (see full listing online)

Locations (2 total)

West China Hospital Sichuan University, Chengdu, Sichuan, China
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China